

# ACI's Acclaimed Summit on Life Sciences IP Due Diligence is taking place virtually November 9-10, 2020

*Meet thought leaders from top Life Sciences companies that will help you develop strategies for the best results of the IP due diligence process.*

NEW YORK CITY, UNITED STATES,  
October 26, 2020 /EINPresswire.com/ --

ACI is excited to offer our [4th Annual Summit on Life Sciences](#) in an interactive, virtual format. This is the only forum devoted to providing corporate and IP counsel with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic due diligence on any deal.



Great panels, lots of diversity of practice, and lots of seasoned practitioners."  
*Senior Intellectual Property Counsel*

Gain insights from Key Industry Stakeholders including:

- Akebia Therapeutics
  - Akorn Pharmaceuticals
  - Boehringer Ingelheim USA Corporation
  - Cantel Medical
  - Eisai Inc.
  - Eli Lilly and Company
- 
- Flagship Pioneering
  - Genentech
  - Gilead Sciences
  - Merck
  - Novartis Pharmaceuticals
  - Omega Therapeutics
  - Pieris Pharmaceuticals
  - Roche
  - Sanofi
  - Takeda

New, interactive sessions will have you fully engaged and learning from senior industry insiders.

Sessions include:

- Interactive Ethics Lab: Overcoming Common Challenges and Ethical Dilemmas in Life Sciences IP Due Diligence
- Interactive Case Study: Avoiding Missteps When Conducting IP Due Diligence in Connection with Distressed Companies and Distressed Assets
- Pre-Conference Primer: Life Sciences IP Due Diligence 101 – Preparing Your Due Diligence Checklist and Managing the Process from Soup to Nuts
- Freedom to Operate BootCamp: A Comprehensive Tactical Guide to Mastering the FTO Search

To see our full list of speakers, [view the brochure](#).

[Register to secure your spot](#).

Shannon Kao  
American Conference Institute  
s.kao@canadianinstitute.com

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/529285640>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.